LAS VEGAS, Aug. 8, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals, Inc. (AMEX:LIV), a developer of innovative drugs, announced today that it has entered into an exclusive licensing agreement with Georgetown University for a new innovative drug SP-6300 to treat Cushing's syndrome.
